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Abstract 
Background: Antiretroviral therapy (ART) improves the survival and quality of life of HIV-positive individuals, but the 
effects of long-term ART use do eventually manifest. The Complications of Long-Term Antiretroviral Therapy cohort 
study in Uganda (CoLTART) was established to investigate the metabolic and renal complications of long-term ART 
use among Ugandan adults. We describe the CoLTART study set-up, aims, objectives, study methods, and also report 
some preliminary cross–sectional study enrolment metabolic and renal complications data analysis results.
Methods: HIV-positive ART naïve and experienced adults (18 years and above) in Uganda were enrolled. Data on 
demographic, dietary, medical, social economic and behaviour was obtained; and biophysical measurements and 
a clinical examination were undertaken. We measured: fasting glucose and lipid profiles, renal and liver function 
tests, full blood counts, immunology, virology and HIV drug resistance testing. Plasma samples were stored for future 
studies.
Results: Between July 2013 and October 2014, we enrolled 1095 individuals, of whom 964 (88.0%) were ART expe-
rienced (6 months or more), with a median of 9.4 years (IQR 7.0–9.9) on ART. Overall, 968 (88.4%) were aged 35 years 
and above, 711 (64.9%) were females, 608 (59.6%) were or had ever been on a Tenofovir ART regimen and 236 (23.1%) 
on a Protease Inhibitor (PI) regimen. There were no differences in renal dysfunction between patients on Tenofovir 
and Non-Tenofovir containing ART regimens. Patients on PI regimens had higher total cholesterol, lower high density 
lipoprotein, higher low density lipoprotein, higher triglycerides, and a high atherogenic index for plasma than the 
non-PI regimen, p = 0.001 or < 0.001. Patients on Non-PI regimens had higher mean diastolic hypertension than 
patients on PI regimens, p < 0.001.
Conclusions: Our finding of no differences in renal dysfunction between patients on Tenofovir and those on Non-
Tenofovir containing ART regimens means that Tenofovir based first line ART can safely be initiated even in settings 
without routine renal function monitoring. However, integration of cardiovascular risk assessment, preventive and 
curative measures against cardiovascular disease are required. The CoLTART cohort is a good platform to investigate 
the complications of long-term ART use in Uganda.
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Background
Since the Universal roll-out of antiretroviral therapy 
(ART) in 2004, access to and availability of ART has 
improved. By June 2016, globally 18.2 million HIV-posi-
tive people were receiving ART, up from 15.8 million in 
June 2015 and 7.5 million in 2010 [1]. In Uganda, 750,896 
(50%) HIV-positive people were receiving ART by 
December 2014 [2]. Although in industrialised countries 
ART has been used for over 20 years, in sub-Sahara, ART 
availability in public health facilities only began around 
2004. In Uganda, reports suggest that the prevalence of 
non-infectious diseases like diabetes mellitus, and car-
diovascular morbidity and mortality are increasing [3, 4].
Long-term ART use is associated with metabolic, car-
diovascular, hepatic, renal, bone, bone marrow and other 
complications or toxicities [5–9]. These complications 
of ART are variably associated with all major classes of 
ARVs. The three most common metabolic abnormalities 
that are related to ART are dyslipidaemia, lipodystrophy 
and dysregulation of glucose metabolism [5–9]. Renal 
impairment among HIV-positive individuals may be due 
to HIV associated nephropathy, co-infections and co-
morbidities, or renal toxicity from ART and concurrent 
medications [10, 11]. Due to its cost, in resource limited 
settings Tenofovir had been reserved for use with Pro-
tease inhibitors in second line ART regimens. The WHO 
recommendation to use Tenofovir in first line ART regi-
mens has been widely adopted by ART programmes in 
Africa including Uganda, Kenya and Tanzania [12–15]. 
However, Tenofovir is often associated with renal toxic-
ity, manifesting as a decline in estimated glomerular fil-
tration rate (eGFR), proximal renal tubular dysfunction 
and acute renal failure especially among patients with 
risk factors for kidney disease [16–23]. It has been sug-
gested, that patients of African origin are at higher risk 
for HIV associated kidney disease [24], a suggestion that 
remains to be clarified by studies conducted in Africa. 
Therefore, for long-term HIV care in Africa, health work-
ers need research-based evidence on renal function 
beyond 5  years of Tenofovir containing ART, and how 
these patients should be monitored.
In sub-Saharan Africa, there is scarce literature on 
the long-term impact of ARVs toxicities among African 
populations. Current ART guidelines in sub-Saharan 
Africa are therefore based on evidence from industri-
alised country settings. However, there are differences 
between industrialised countries and sub-Saharan Africa 
in terms of patient profiles, background risk factors for 
co-infections, co-morbidities, ART regimen choices and 
drug toxicities. In 2013, the Complications of Long-Term 
Antiretroviral Therapy (CoLTART) cohort was there-
fore established by the MRC/UVRI Uganda Research 
Unit on AIDS (MRC/UVRI Uganda Unit) as a platform 
for studying the complications of long-term ART among 
Ugandan HIV-positive adults. The study aimed at exam-
ining the metabolic and renal complications of long-
term ART use among Ugandan HIV-positive adults aged 
18 years and above. In this paper, we describe the CoL-
TART study set-up, aims, objectives, study methods, and 
also report some preliminary cross-sectional study enrol-
ment renal and metabolic complications data analysis 
results.
Methods
The CoLTART study design and settings
The CoLTART study was a prospective clinical cohort 
conducted at two study clinics; (a) the former Develop-
ment of Antiretroviral therapy in Africa (DART) Trial 
study clinic in Entebbe [25], and (b) the former Rural 
Clinical Cohort (RCC) study clinic in Kyamulibwa, 
approximately 120 kilometres from Entebbe [26]. The 
MRC/UVRI Uganda Unit’s Head offices and central Clin-
ical Diagnostic Laboratory Services (CDLS) are located 
in Entebbe.
CoLTART study aims and objectives
The CoLTART study aims were to study the metabolic 
and renal complications of long-term ART, and the 
long-term treatment outcomes of a triple nucleoside 
first ART regimen. The primary objectives were to com-
pare the: (a) mean values for cardio-metabolic markers 
among patients on a Protease Inhibitor (PI)-containing 
ART regimen and those on a non PI-containing regimen. 
(b) Mean values of proximal renal tubular function and 
eGFR among patients on a Tenofovir (TDF) containing 
regimen and those on a non-TDF containing regimen.
CoLTART study participants
Between July 2013 and October 2014, CoLTART study 
participants (Fig. 1) who were HIV-positive adults (aged 
18 and above) on ART were recruited from; (a) the for-
mer DART Trial Cohort, which was a randomised clini-
cal trial of monitoring strategy for the management of 
ART in adults with HIV infection in Africa established in 
2003 [25]. (b) The former RCC which was an open clini-
cal cohort established in 1990 to study the natural his-
tory of HIV infection [26] and later the impact of ART 
after its introduction in 2004 [27–30]. ART naïve HIV-
positive study participants, but who were eligible to initi-
ate ART were enrolled from: (a) the RCC, (b) the General 
Population Cohort that was established in 1989 in rural 
southwest Uganda to examine the dynamics of the HIV 
epidemic [31] and (c) the Entebbe Pre-ART cohort that 
was established in 1995 as a double blind, randomised 
and placebo controlled trial of a 23-valent pneumococcal 
polysaccharide vaccine in HIV-positive adult Ugandans 
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[32]. ART was provided according to existing National 
ART guidelines [13, 33]. The study included HIV-positive 
adults (aged 18  years and above), who were on ART or 
eligible to initiate ART, not participating in another study, 
who were willing to undergo regular clinical, biophysical 
and laboratory evaluation and to complete a study ques-
tionnaire. Individuals who were too sick to undergo study 
procedures, unable or unwilling to give informed consent 
were excluded from the study.
Participants’ enrolment and follow‑up
Consenting eligible individuals were enrolled, and 
requested to fast from midnight of the day prior enrol-
ment, and they received a drink and snack after the blood 
draw and biophysical measurements. We measured 
the body weight using the Seca digital measuring scale, 
height using a portable Seca 213 Leicester stadiometer 
and body circumferences using a non-stretchable Seca 
201 Ergonomic Circumference Measuring tape (Table 1). 
Details of the methods for taking biophysical measure-
ments and calibrating the equipment used have been 
described elsewhere [34]. Blood pressure and pulse rate 
were measured using the Omron M6 comfort automatic 
blood pressure monitor. At enrolment and six monthly 
follow-up visits, a modified WHO STEPS cardiovascular 
risk data surveillance questionnaire was administered to 
collect the relevant data [35]. Every three months, par-
ticipants renewed their prescriptions for ART and/or 
cotrimoxazole or Dapsone prophylaxis and adherence 
data was collected using self-report and pill count. Every 
6 months (Table 1), participants attended for scheduled 
follow-up visits, and they fasted as done at enrolment, 
and the data collected were recorded on a follow-up 
questionnaire and clinical examination form. At these 
6 monthly visits, participants also renewed their medi-
cines prescriptions and adherence data was collected. 
Participants who fell sick in between the scheduled visits 
attended the study clinics to receive medical care.
Laboratory procedures
Specimen collection and storage
At enrolment and follow-up visits, about 10–15  ml of 
venous blood were collected in three tubes as follows: 
(a) 4 ml of whole blood in an EDTA tube for haematol-
ogy, immunology and viral loads measurements. (b) 5 ml 
plain serum tube blood to measure fasting serum lipids; 
renal and liver function tests. (c) 4  ml Sodium fluoride 
tube blood to measure fasting blood glucose. At enrol-
ment only, serum for hepatitis B serology and two ali-
quots of plasma were stored at −80 °C for future testing. 
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Fig. 1 Sources of enrolled CoLTART cohort study participants
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Blood tubes were labelled with a unique individual study 
and laboratory number and transferred under appro-
priate conditions to the CDLS laboratory for analysis. 
At one follow-up visit, a 4 ml of whole blood sample in 
an EDTA tube was stored at −80  °C for future genom-
ics testing. Participants with viral loads of 1000 copies/
ml or higher had antiretroviral drug resistance testing 
done. Participants (excluding women in their menses) 
provided a fresh midstream urine specimen in a plain 
sterile container, that was later portioned in two plastic 
centrifuge tubes (one plain for urine creatinine and the 
other acidified for urine phosphates measurements), and 
a dipstick strip test was done on the urine remaining in 
the container.
Laboratory testing
All samples were analysed in the MRC/UVRI Uganda 
Unit’s CDLS laboratories. The Clinical chemistry ana-
lyser, COBAS Integra 400 plus (Roche Diagnostics) was 
used to measure fasting serum lipids and blood glucose, 
and renal and liver function test parameters. Full blood 
counts were measured using the Coulter AcT5 Diff CP 
Analyser (Beckman Coulter, USA). CD4 cell counts were 
measured using either the FACSCount or FACSCalibur 
machine (Becton–Dickinson, USA). Plasma HIV-1 RNA 
was quantified using the COBAS Ampliprep/Taqman 
V2.0 HIV-1 viral load assay (Roche Molecular Diagnos-
tics [RMD], NJ, USA) with a lower detection limit of 20 
copies/ml. For urine strip testing, we used the Siemens 
Multistix 10SG and read with Clinitek Status Analyzer 
(Siemens Healthcare Diagnostics). For ARV drug resist-
ance, PCR and sequencing reactions were conducted and 
the sequences submitted to the Stanford University HIV 
Drug Resistance database. The surveillance drug resist-
ance mutations were identified using the 2009 WHO 
list for surveillance of transmitted drug resistances [36], 
using the Stanford calibrated population resistance anal-
ysis tool version 5.0 beta [37]. Sequences with genetic 
mixtures of wild-type and mutant sequences at amino 
acid sites that code for SDRMs were considered to be 
drug-resistant.
Laboratory data quality assurance
Standard operating procedures and internal quality 
measurements ensured internal quality control. The 
United Kingdom National External Quality Assurance 
Service, College of American Pathologists and the Royal 
College of Pathologists of Australasia were used for 
Table 1 Measurements and data collected in the CoLTART cohort
Phase Data collected at enrolment
Baseline
July 2013
Demographic data and self-reported social economic status
Medical, dietary and socio-economic and behavioural risk factors
Biophysical measurements: weight, height, blood pressure, pulse rate; waist, hip and mid-upper arm circumferences
Clinical examination
Antiretroviral therapy and cotrimoxazole/dapsone adherence
Laboratory measurements data
Biochemistry
(i) Fasting blood lipid profiles: total cholesterol, triglycerides, low density lipoproteins, high density lipoproteins
(ii) Fasting blood glucose
(iii) Renal function tests: urine strip testing, phosphates and creatinine
Serum phosphates, creatinine and urea
(vi) Liver function tests: alanine transaminase, aspartate transaminase, alkaline phosphatase and bilirubin
Haematology and immunology
(i) Full blood counts
(ii) CD3, CD4 and CD8 cell counts
Virology
(i) HIV viral loads
(ii) HIV drug resistance testing—when indicated
Serology (for future testing)
Serum for Hepatitis B virus serology and plasma aliquots stored at −80 °C
6 monthly
Follow-up
January 2014
Data collected at follow up
Biophysical measurements
Medical, dietary and socio-economic and behavioural risk factors
Clinical examination
Antiretroviral therapy and cotrimoxazole/dapsone adherence
Laboratory measurements
Fasting blood glucose and lipid profiles
Renal and liver function tests
Full blood counts and immunology—CD3, CD4 and CD8
HIV viral loads
HIV drug resistance testing—when indicated
Whole blood for genomics studies stored at −80 °C (once)
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External quality Assurance for both haematological and 
biochemistry assays. Virology Quality Assurance Scheme 
(Rush University, Chicago, IL) was used for External 
Quality Assurance for virological assays.
Data management and statistical methods
Data was collected on the case report forms which 
together with the Laboratory result forms were sorted, 
batched and submitted to the Statistics section for data 
entry. Data was managed in accordance with the ICH-
GCP data management principles using a single Ms. 
Access study database using common identifiers to incor-
porate relevant retrospective data from the DART Trial 
Cohort and RCC databases. All the data was backed 
up on a central Unit server with a password restricted 
access. Enrolment statistical analyses were done in 
STATA 13 (Stata Corporation, College Station, USA). 
Participants’ socio-demographic and economic charac-
teristics, lifestyle and anthropometric as well as clinical, 
history of diseases and ART exposure were examined 
across study sites and by sex. Renal function outcomes 
were determined using measured renal function tests, 
and calculated Fractional Tubular reabsorption of phos-
phates and estimated glomerular filtration rate (eGFR). 
Different formulae were used to calculate eGFR; (a) the 
Cockcroft-Gault formulae with and without body surface 
area adjustment, (b) the Modified Diet in Renal Disease 
formulae with race adjustment and (c) the Chronic Kid-
ney Disease Epidemiology.
Abnormal renal function outcomes were defined as: 
serum urea of more than 11.9 mmol/l, serum creatinine 
of more than 109 μmol/l, Fractional Tubular phosphates 
reabsorption of less than 82% and eGFR less than 60 ml/
min/1.73  m2, Diabetis mellitus as a measured fasting 
blood glucose more than or equal to 6.4 mmol/l or his-
tory of and or being on medications for diabetis mellitus. 
Hypertension was a measured systolic blood pressure 
(SBP) of more than or equal to 140  mmHg or diastolic 
blood pressure (DBP) more than or equal to 90  mmHg 
or any history of and or being on medications for hyper-
tension. The renal function outcomes were compared 
across the Tenofovir exposure groups: (i) non-Tenofovir 
containing ART regimen (Non-TDF), (ii) Tenofovir con-
taining ART regimen (TDF-ART) and (iii) previously on 
Tenofovir containing ART regimen but stopped (TDF-
stopped). Mean values of renal function outcomes were 
compared by Tenofovir exposure using general linear 
models. General linear regression models adjusted for 
several factors were used to compare mean values of 
renal function outcomes across groups of Tenofovir 
exposure categories. The mean values of SBP, DBP, total 
serum cholesterol, high density lipoprotein, low density 
lipoprotein, triglyceride, atherogenic index of plasma and 
fasting blood glucose and Framingham risk score were 
compared between PI-based and non-PI based ART regi-
mens using general linear regression models, adjusted for 
duration on ART and other factors.
Results
Between July 2013 and October 2014, we assessed 1108 
HIV-positive individuals for study eligibility, of whom 
1095 (98.8%) were enrolled into the study. At the Entebbe 
site, 673 individuals were assessed for study eligibil-
ity and 666 (99.0%) were enrolled and 7 (1.0%) were not 
enrolled because; 3 (0.4%) were participating in another 
study, 3 (0.4%) did not return for enrolment while 1 
(0.1%) died before enrolment. At the Kyamulibwa site, 
436 individuals were assessed for study eligibility and 429 
(98.4%) were enrolled, 7 (1.6%) were not enrolled because 
3 (0.7%) requested for transfer to other ART care centres, 
1 (0.2%) had mental illness, 1 (0.2%) declined consent 
for participation, 1 (0.2%) defaulted and 1 (0.2%) died 
before enrolment. Of the 1095 individuals enrolled, 964 
(88.0%) were ART experienced (6 months or more) with 
a median of 9.4 years (IQR 7.0–9.9) on ART. Overall, 968 
(88.4%) were aged 35 years and above, 711 (64.9%) were 
females, 608 (59.6%) were or had ever been on a Teno-
fovir containing ART regimen and 236 (23.1%) on a Pro-
tease Inhibitor containing ART regimen. Participants at 
the urban (Entebbe) site were older, mean age (SD); 46.1 
(8.1) vs 42.7 (10.6) years and had a higher education level; 
54.3% vs 15.4% had attained secondary level education 
and above. Whereas most of rural participant were peas-
ants (69.5%), those from the urban site were mainly in 
gainful employment or self-employed—80.3% (Table 2).
Among our study population, the overall prevalence 
of hypertension was 14.5%, Diabetes mellitus—2.1% 
and renal disease—0.6%. Participants from the urban 
site had been on ART for a longer duration, with 90.7% 
on ART for 9  years and over compared to 11.7% at the 
rural site. Overall, 236 (23.1%) of our participants were 
on a PI containing ART regimen with a higher propor-
tion of patients being at the urban Entebbe site; 32.4% 
compared to 7.6% among those at the rural Kyamulibwa 
site and 608 (59.6%) were or had ever been on a Tenofo-
vir containing ART regimen; 78.3% of those at the urban 
site and 28.3% at the rural site (Table 3). We found that 
among individuals on long-term ART; (a) there were no 
differences in renal dysfunction (glomerular function and 
renal tubular function) between patients on Tenofovir 
containing and Non-Tenofovir containing ART regimens 
(Table  4). (b) Patients on PI containing ART regimens 
had higher total cholesterol, lower high density lipopro-
tein, higher low density lipoprotein, higher triglycerides, 
and a high atherogenic index for plasma than patients on 
non-PI containing ART regimen, p = 0.001 or < 0.001. (c) 
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Table 2 Characteristics of participants at enrolment into the CoLTART study by sex and study site
Characteristic All combined Entebbe site Kyamulibwa site
n (%) All, n (%) Sex All, n (%) Sex
Females, n (%) Males, n (%) Females, n (%) Males, n (%)
All by site 1095 666 459 (68.9) 207 (31.1) 429 252 (58.7) 177 (41.3)
Age, years
 18–34 127 (11.6) 34 (5.1) 29 (6.3) 5 (2.4) 93 (21.8) 65 (26.0) 28 (15.8)
 35–49 649 (59.3) 426 (64.0) 295 (64.3) 131 (63.3) 222 (52.0) 126 (50.4) 96 (54.2)
 50+ 319 (29.1) 206 (30.9) 135 (29.4) 71 (34.3) 112 (26.2) 59 (23.6) 53 (30.0)
 Mean age, years (SD) 44.8 (9.3) 46.1 (8.1) 45.5 (8.1) 47.3 (7.9) 42.7 (10.6) 41.6 (10.4) 44.3 (10.8)
Marital status
 Never married 87 (8.0) 28 (4.2) 24 (5.2) 4 (1.9) 59 (13.8) 40 (15.9) 19 (10.7)
 Married/cohabiting 469 (42.8) 263 (39.5) 105 (22.9) 158 (76.3) 206 (48.0) 93 (36.9) 113 (63.8)
 Separated/divorced 265 (24.2) 150 (22.5) 126 (27.5) 24 (11.6) 115 (26.8) 78 (31.0) 37 (20.9)
 Widowed 274 (25.0) 225 (33.8) 204 (44.4) 21 (10.1) 49 (11.4) 41 (16.2) 8 (4.5)
Education level
 Incomplete primary 498 (45.5) 185 (27.8) 133 (29.0) 52 (25.1) 313 (73.0) 181 (71.8) 132 (74.6)
 Complete primary 169 (15.4) 119 (17.9) 85 (18.5) 34 (16.4) 50 (11.6) 27 (10.7) 23 (13.0)
 Secondary+ 428 (39.1) 362 (54.3) 241 (52.5) 121 (58.5) 66 (15.4) 44 (17.5) 22 (12.4)
Employmenta
 Peasant/farmer 362 (33.1) 64 (9.6) 45 (9.8) 19 (9.2) 298 (69.5) 179 (71.0) 119 (67.2)
 Gainful employment 221 (20.2) 174 (26.2) 113 (24.7) 61 (29.5) 47 (11.0) 26 (10.3) 21 (11.9)
 Self-employed/business 427 (39.0) 360 (54.1) 242 (52.8) 118 (57.0) 67 (15.6) 36 (14.3) 31 (17.5)
 Unemployed 84 (7.7) 67 (10.1) 58 (12.7) 9 (4.3) 17 (3.9) 11 (4.4) 6 (3.4)
SES score  tertileb
 Low 458 (42.0) 277 (41.9) 222 (48.9) 55 (26.6) 181 (42.2) 111 (44.0) 70 (39.5)
 Middle 413 (37.9) 245 (37.1) 159 (35.0) 86 (41.5) 168 (39.2) 104 (41.3) 64 (36.2)
 High 219 (20.1) 139 (21.0) 73 (16.1) 66 (31.9) 80 (18.6) 37 (14.7) 43 (24.3)
Tobacco  consumptionc
 Never 898 (82.1) 575 (86.4) 430 (93.8) 145 (70.0) 323 (75.2) 234 (92.8) 89 (50.3)
 Ex-smoker 105 (9.6) 61 (9.2) 14 (3.1) 47 (22.7) 44 (10.3) 4 (1.6) 40 (22.6)
 Current 91 (8.3) 29 (4.4) 14 (3.1) 15 (7.2) 62 (14.5) 14 (5.6) 48 (27.1)
Alcohol  consumptiond
 Never 408 (37.6) 248 (37.7) 186 (41.1) 62 (30.4) 160 (37.4) 112 (44.4) 48 (27.1)
 Ever >1 month 383 (35.3) 255 (38.9) 183 (40.4) 72 (35.3) 128 (29.7) 80 (31.7) 48 (27.1)
 Within <1 month 295 (27.1) 154 (23.4) 84 (18.5) 70 (34.3) 141 (32.9) 60 (23.9) 81 (45.8)
Work involves moderate/vigorous  activitye
 No 494 (45.2) 433 (65.1) 333 (72.7) 100 (48.3) 61 (14.3) 48 (19.0) 13 (7.4)
 Yes 599 (54.8) 232 (34.9) 125 (27.3) 107 (51.7) 367 (85.7) 204 (81.0) 163 (92.6)
Days/week-animal  proteinsf
 0 300 (27.6) 127 (19.3) 98 (21.6) 29 (14.1) 173 (40.3) 123 (48.8) 50 (28.2)
 1 or 2 487 (44.8) 298 (45.3) 210 (46.4) 88 (42.9) 189 (44.1) 98 (38.9) 91 (51.4)
 3+ 300 (27.6) 233 (35.4) 145 (32.0) 88 (42.9) 67 (15.6) 31 (12.3) 36 (20.4)
Adds salt to  foodg
 No 625 (57.8) 399 (61.0) 283 (63.0) 116 (56.6) 226 (52.8) 148 (58.7) 78 (44.3)
 Yes 457 (42.2) 255 (39.0) 166 (37.0) 89 (43.4) 202 (47.2) 104 (41.3) 98 (55.7)
Type of oil/fat used in  cookingh
 None 146 (13.6) 68 (10.5) 43 (9.6) 25 (12.3) 78 (18.3) 54 (21.4) 24 (13.7)
 Vegetable oil 793 (73.6) 488 (75.1) 334 (74.9) 154 (75.5) 305 (71.4) 183 (72.6) 122 (69.7)
 Animal fat 111 (10.3) 73 (11.2) 53 (11.9) 20 (9.8) 38 (8.9) 13 (5.2) 25 (14.3)
 Others/none in particular 27 (2.5) 21 (3.2) 16 (3.6) 5 (2.5) 6 (1.4) 2 (0.8) 4 (2.3)
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Patients on non-PI containing ART regimen had higher 
diastolic hypertension than patients on PI containing 
ART regimen, p < 0.001 (Table 5).
Discussion
In sub Saharan Africa, there is paucity of data on the 
complications of long-term ART use generated from the 
region. The CoLTART cohort therefore provides a good 
platform to investigate the complications of long-term 
ART in a Ugandan population. In this cross-sectional 
analysis of data collected at enrolment of patients who 
had been on ART for a median of 9.4 years, we found no 
differences in renal function (eGFR and fractional tubular 
phosphate reabsorption) between patients on Tenofovir 
and Non-Tenofovir containing ART regimens. However, 
we found that patients on PI containing ART regimens had 
higher cardiometabolic risk factors including higher total 
cholesterol, lower high density lipoprotein, higher low 
density lipoprotein, higher triglycerides, and a high athero-
genic index for plasma compared to the non-PI regimen.
These findings are reassuring against concerns about 
Tenofovir induced renal toxicity, especially as it is now 
recommended by WHO for initiating ART, and has been 
widely adopted by ART programmes in many resource 
limited countries including Uganda [12–15]. Short to 
medium follow up studies have reported an association 
between Tenofovir and renal dysfunction, leading to glo-
merular and proximal renal tubular damage and acute 
renal failure [17–20]. Our failure to find differences in 
renal dysfunction by Tenofovir use might be due to the fact 
that most of our patients had been on ART for more than 
9  years. Similarly, other previous studies have reported 
that the loss in eGFR attributable to Tenofovir seemed to 
occur during the early years of exposure between 0.5 and 
31.2 months and stabilized after that [38–41].
As HIV infected individuals live longer due to 
improved survival on ART, cardiometabolic co-morbidity 
will manifest, and the association of HIV infection and 
cardiovascular disease will be compounded by ART use. 
The association of PI containing ART regimen and car-
diometabolic risk is important since PIs are the backbone 
of second line ART regimens in resource limited settings. 
With the advocacy and availability of virological moni-
toring of patients on ART, more patients with virological 
failure will be identified and switched to PI containing 
second line ART regimens. HIV care programmes in 
resource limited settings therefore need to integrate 
CVD risk assessment and preventive measures, including 
routine biochemical and biophysical monitoring as well 
as stocking of lipid lowering drugs, increasing physical 
exercises, dietary adjustments.
Study strengths
The CoLTART cohort study participants have been on 
ART for close to a decade and thus enables assessment 
of the temporal relationship between ART and ART 
complications. The DART and RCC cohorts have sys-
tematically collected data on clinical, immunological and 
virological treatment outcomes, ARV toxicities, with reg-
ular haematology, liver and kidney function biochemical 
test results that can be used retrospectively. Stored serum 
and plasma samples that can be used for various analyses 
for the status during the early ART period (DART) and 
during the Pre-ART and early ART periods (RCC) are 
also available. The MRC/UVRI Uganda Unit’s CDLS has 
the capacity for analysing and storing research samples.
Study weakness
Study participants of the former cohorts may not be rep-
resentative of the general HIV-positive population, and 
those who were available for enrolment may be a biased 
sample due to their longer survival. The study included 
limited outcomes, other long-term ART complications, 
such as reduced bone mineral density and osteoporo-
sis were not studied due to the costs of the non-invasive 
DXA (DECK-sa) scan, a procedure used to measure bone 
All combined combines both Entebbe and Kyamulibwa sites. SES score tertile—Social Economic Status score computed from asset index based on household 
ownership of items
Number of participants with missing data: aEmployment—1, bSES score tertile—5, cTobacco consumption—1, dAlcohol consumption—9, eWork involves moderate/
vigorous activity—2, fDays/week-animal proteins—8, gAdds salt to food—13, hType of oil/fat used in cooking—18, iTotal teaspoons of sugar added to drink/day—24
Table 2 continued
Characteristic All combined Entebbe site Kyamulibwa site
n (%) All, n (%) Sex All, n (%) Sex
Females, n (%) Males, n (%) Females, n (%) Males, n (%)
Total teaspoons of sugar added to drink/dayi
 <3 337 (31.5) 247 (38.4) 149 (33.7) 98 (48.8) 90 (21.0) 46 (18.3) 44 (25.0)
 4/7 428 (39.9) 279 (43.4) 202 (45.7) 77 (38.3) 149 (34.8) 84 (33.3) 65 (36.9)
 8+ 306 (28.6) 117 (18.2) 91 (20.6) 26 (12.9) 189 (44.2) 122 (48.4) 67 (38.1)
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density, as well as mineral content in the body. In our 
study, a small number of patients; 50 (8.9%) had discon-
tinued Tenofovir but we did not consider the period since 
Tenofovir was discontinued and the reasons why it was 
discontinued. If Tenofovir was stopped due to Tenofovir 
induced renal dysfunction, this might have biased our 
results. Due to the low prevalence of antibody seroposi-
tivity and confirmed Hepatitis C virus (HCV) RNA infec-
tion in Uganda [42, 43], we did not screen for HCV in 
this study. Other potential sources of bias included the 
Table 3 Medical history of participants at enrolment into the CoLTART study by sex and site
Number of participants with missing data: aDiabetes mellitus history—5, bRenal disease history—1, cMetabolic abnormalities study groups—74 patients who were 
ART naïve at enrolment, dRenal dysfunction study groups—74 patients who were ART naïve at enrolment, eBody Mass Index—22, fHaemoglobin—5, gCD4 cell counts 
at enrolment—75, hViral loads at enrolment-36; the 1059 included the 74 ART naïve individuals pending ART initiation
NNRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor
Medical condition All combined Entebbe site Kyamulibwa site
n (%) All, n (%) Sex All, n (%) Sex
Females, n (%) Males, n (%) Females, n (%) Males, n (%)
All 1095 666 459 (68.9) 207 (31.1) 429 252 (58.7) 177 (41.3)
Hypertension history
 Never had hypertension 936 (85.5) 556 (83.5) 378 (82.4) 178 (86.0) 380 (88.6) 222 (88.1) 158 (89.3)
 Ever had hypertension 159 (14.5) 110 (16.5) 81 (17.6) 29 (14.0) 49 (11.4) 30 (11.9) 19 (10.7)
Diabetes mellitus  historya
 No known diabetes mellitus 1067 (97.9) 645 (97.3) 445 (97.4) 200 (97.1) 422 (98.8) 248 (98.8) 174 (98.9)
 Known diabetes mellitus 23 (2.1) 18 (2.7) 12 (2.6) 6 (2.9) 5 (1.2) 3 (1.2) 2 (1.1)
Renal disease  historyb
 No renal disease 1087 (99.4) 659 (99.1) 456 (99.3) 203 (98.5) 428 (99.8) 252 (100.0) 176 (99.4)
 Known renal disease 7 (0.6) 6 (0.9) 3 (0.7) 3 (1.5) 1 (0.2) 0 (0.0) 1 (0.6)
ART exposure, years
 ART naïve 74 (6.8) 27 (4.1) 21 (4.6) 6 (2.9) 47 (11.0) 22 (8.7) 25 (14.1)
 <1 years 79 (7.2) 13 (2.0) 11 (2.4) 2 (1.0) 66 (15.4) 35 (13.9) 31 (17.5)
 1 to <5 years 164 (15.0) 7 (1.1) 6 (1.3) 1 (0.5) 157 (36.6) 98 (38.9) 59 (33.3)
 5 to <9 years 124 (11.3) 15 (2.3) 9 (2.0) 6 (2.9) 109 (25.4) 65 (25.8) 44 (24.9)
 9+ years 654 (59.7) 604 (90.7) 412 (89.8) 192 (92.8) 50 (11.7) 32 (12.7) 18 (10.2)
Metabolic abnormalities study  groupsc
 Non-protease Inhibitor based ART 785 (76.9) 432 (67.6) 306 (69.9) 126 (62.7) 353 (92.4) 212 (92.2) 141 (92.8)
 Protease Inhibitor based ART 236 (23.1) 207 (32.4) 132 (30.1) 75 (37.3) 29 (7.6) 18 (7.8) 11 (7.2)
Renal dysfunction study  groupsd
 Tenofovir containing ART 608 (59.6) 500 (78.3) 337 (76.9) 163 (81.1) 108 (28.3) 64 (27.8) 44 (29.0)
 Non-Tenofovir containing ART 413 (40.5) 139 (21.8) 101 (23.1) 38 (18.9) 274 (71.7) 166 (72.2) 108 (71.1)
Body mass index (kg/m2)e
 <18.5 114 (10.6) 48 (7.4) 29 (6.5) 19 (9.4) 66 (15.4) 29 (11.5) 37 (21.0)
 18.5–24.9 674 (62.8) 365 (56.6) 217 (49.0) 148 (73.3) 309 (72.2) 175 (69.4) 134 (76.1)
 25.0–29.9 218 (20.3) 172 (26.7) 140 (31.6) 32 (15.8) 46 (10.8) 41 (16.3) 5 (2.8)
 ≥30 67 (6.3) 60 (9.3) 57 (12.9) 3 (1.5) 7 (1.6) 7 (2.8) 0 (0.0)
Haemoglobin (g/dl)f
 Normal 908 (83.3) 570 (86.2) 387 (85.1) 183 (88.8) 338 (78.8) 199 (79.0) 139 (78.5)
 Abnormal 182 (16.7) 91 (13.8) 68 (14.9) 23 (11.2) 91 (21.2) 53 (21.0) 38 (21.5)
CD4 cell counts at enrolment (cells/µl)g
 ≤350 307 (30.1) 182 (30.6) 102 (25.2) 80 (42.3) 125 (29.3) 65 (26.1) 60 (33.9)
 351–500 327 (32.1) 171 (28.8) 118 (29.1) 53 (28.0) 156 (36.6) 89 (35.7) 67 (37.9)
 501+ 386 (37.8) 241 (40.6) 185 (45.7) 56 (29.6) 145 (34.0) 95 (38.2) 50 (28.2)
Viral loads at enrolment (cells/ml)h
 ≤1000 copies/ml 823 (77.7) 528 (81.6) 363 (81.2) 165 (82.5) 295 (71.6) 180 (75.3) 115 (66.5)
 >1000 copies/ml 236 (22.3) 119 (18.4) 84 (18.8) 35 (17.5) 117 (28.4) 59 (24.7) 58 (33.5)
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self-reported thus subjectively measured individual level 
exposures especially dietary, socio-economic and behav-
ioural factors. There might have been some inaccuracies 
in tracking time on particular regimens of ART e.g. the 
exact dates of ART switches or substitutions.
Conclusions
Our findings allay fears of Tenofovir renal toxicity and the 
WHO recommendation to use Tenofovir in first line ART 
can safely be implemented even in resource limited set-
tings with limited renal function monitoring. However, 
further evaluation of renal function among patients on 
Tenofovir beyond 10 years is advised. Integration of car-
diovascular risk assessment, institution of preventive and 
curative or control remedies against cardiovascular dis-
ease are recommended.
Data available
Data available includes demographic, social economic sta-
tus, medical, dietary and lifestyle risk factors. Biophysi-
cal measurements data available includes weight, height, 
blood pressure and pulse rate; waist, hip and mid-upper 
Table 4 Proportion of renal dysfunction/failure, and adjusted mean differences in renal function measures by TDF expo-
sure among 964 adults on ART for more than 6 months
Mean difference adjusted for site, duration on ART, smoking status, social-economic status, log viral load, CD4 cell count, hypertension and Glucose; Renal 
dysfunction/failure defined as <90 for estimated Glomerular Filtration Rates, >11.9 mmol/l for serum Urea, >109 μmol/l for serum creatinine and <0.81 mmol/l for 
serum phosphates (Hypophosphataemia)
eGFR estimated glomerular filtration rate, BSA body surface area adjustment, CKD-Epi Chronic Kidney Disease Epidemiology formula, MDRD Modified Diet in Renal 
Disease formulae with race adjustment
Renal function assessment parameter Renal dysfunction/failure, n (%) Adjusted mean differences  
(95% CI), non-TDF as reference
p value
eGFR (Cockcroft-Gault, adj for BSA)
 Non-TDF 99/378 (26.2%) Ref 0.797
 TDF 142/501 (28.3%) −2.15 (−8.53 to 4.22)
 TDF-stopped 14/50 (28.0%) −0.62 (−12.74 to 11.50)
eGFR (Cockcroft-Gault, without BSA adj)
 Non-TDF 141/379 (37.2%) Ref 0.914
 TDF 196/502 (39.0%) −2.42 (−14.45 to 9.62)
 TDF-stopped 19/50 (38.0%) −3.01 (−25.90 to 19.89)
eGFR (CKD-Epi)
 Non-TDF 60/383 (15.7%) Ref 0.837
 TDF 109/514 (21.2%) −0.88 (−3.84 to 2.08)
 TDF-stopped 9/50 (18.0%) −0.78 (−6.42 to 4.87)
eGFR (MDRD with race)
 Non-TDF 28/383 (7.3%) Ref 0.872
 TDF 57/514 (11.1%) −0.61 (−8.09 to 6.87)
 TDF-stopped 4/50 (8.0%) 3.11 (−11.14 to 17.36)
Fractional tubular PO4 reabsorption
 Non-TDF 16/339 (4.7%) Ref 0.131
 TDF 16/386 (4.1%) −0.74 (−1.84 to 0.36)
 TDF-stopped 1/42 (2.4%) 1.12 (−0.92 to 3.15)
Serum urea
 Non-TDF 0/382 (0.0%) Ref 0.252
 TDF 2/514 (0.4%) 0.03 (−0.19 to 0.25)
 TDF-stopped 0/50 (0.0%) 0.35 (−0.07 to 0.77)
Serum creatinine (μmol/l)
 Non-TDF 4/383 (1.0%) Ref 0.336
 TDF 10/514 (1.9%) 2.03 (−1.40 to 5.46)
 TDF-stopped 3/50 (6.0%) 3.98 (−2.55 to 10.51)
Serum phosphates (mmol/l)
 Non-TDF 64/383 (16.7%) Ref 0.575
 TDF 50/503 (9.9%) 0.01 (−0.04 to 0.06)
 TDF-stopped 8/48 (16.7%) −0.04 (−0.13 to 0.05)
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arm circumferences. Clinical examination and ART and 
cotrimoxazole/dapsone adherence data is also avail-
able. Available laboratory data includes: fasting blood 
glucose and lipid profiles (total cholesterol, triglycerides, 
low density lipoproteins, high density lipoproteins); renal 
function tests (Urine strip test, phosphates and creatinine 
and serum phosphates, creatinine and urea). Full blood 
counts, immunology (CD3, CD4 and CD8), viral loads and 
HIV drug resistance test results for blood samples with 
viral loads ≥1000  copies/ml. Liver function tests (alanine 
Table 5 Proportion of abnormal values for CVD risk factors and differences in mean values of CVD risk measures by PI 
exposure among the 964 adults on ART for more than 6 months
Mean differences adjusted for site, duration on ART, sex, age-groups, smoking status, alcohol consumption, days/week-animal proteins, salt and sugar intake, physical 
activity, social-economic status, log viral load, CD4 cell count
HDL high density lipoprotein, LDL Low Density Lipoprotein, AIP atherogenic index for plasma, BMI body mass index
CVD risk measure Abnormal values  
for CVD risk, n (%)
ADJUSTED mean differences  
(95% CI), non-PI as reference
p value
Total cholesterol ≥5.2 μmol/l
 Non-PI regimen 176/714 (24.6%) Ref <0.001
 PI regimen 121/230 (52.6%) 0.78 (0.57 to 0.98)
HDL <1 mmol/l (males), <1.3 mmol/l (females)
 Non-PI regimen 265/714 (37.1%) Ref 0.001
 PI regimen 67/230 (29.1%) 0.12 (0.05 to 0.20)
LDL ≥3.4 mmol/l
 Non-PI regimen 144/714 (18.6%) Ref <0.001
 PI regimen 93/230 (40.3%) 0.45 (0.29 to 0.62)
Total cholesterol/HDL ratio (>5.1)
 Non-PI regimen 90/714 (12.6%) Ref 0.420
 PI regimen 42/230 (18.3%) 0.10 (−0.15 to 0.35)
Triglycerides ≥1.69 mmol/l
 Non-PI regimen 109/713 (15.3%) Ref <0.001
 PI regimen 99/230 (43.0%) 0.52 (0.24 to 0.80)
Glucose (>6.4 mmol/l)
 Non-PI regimen 26/714 (3.6%) Ref 0.814
 PI regimen 7/231 (3.0%) 0.00 (−0.03 to 0.04)
Systolic blood pressure (≥140 mmHg)
 Non-PI regimen 110/707 (15.6%) Ref 0.060
 PI regimen 19/234 (8.1%) −3.120 (−6.413 to 0.174)
Diastolic blood pressure (≥90 mmHg)
 Non-PI regimen 112/707 (15.8%) Ref <0.001
 PI regimen 13/234 (5.6%) −3.931 (−5.967 to 1.895)
AIP  log10 (Triglycerides/HDL) ≥0.1
 Non-PI regimen 183/713 (25.7%) Ref <0.001
 PI regimen 102/230 (44.3%) 0.12 (0.07 to 0.17)
Abnormal BMI (≥30 kg/m2)
 Non-PI regimen 44/703 (6.3%) Ref 0.074
 PI regimen 17/231 (7.3%) −2.370 (−5.005 to 0.264)
Abnormal waist circumference [≥94 cm (men)/≥80 (women)]
 Non-PI regimen 287/706 (40.6%) Ref 0.805
 PI regimen 94/234 (40.2%) −0.202 (−1.829 to 1.425)
Abnormal waist/hips ratio [>0.95 (men)/>85 (women)]
 Non-PI regimen 369/706 (52.3%) Ref 0.118
 PI regimen 133/234 (56.8%) 0.008 (−0.002 to 0.019)
Abnormal Framingham score (>10%)
 Non-PI regimen 130/703 (18.5%) Ref 0.434
 PI regimen 28/229 (12.2%) −0.344 (−1.218 to 0.530)
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transaminase, aspartate transaminase, alkaline phosphatase 
and bilirubin). Stored samples are also available for Hepati-
tis B virus serology, genomic studies and other studies.
Data resource access
The CoLTART database has data on the participants bio-
physical measurements, clinical examination findings 
and laboratory measurements. All data from the cohort 
are managed by the Statistics Section of the MRC/UVRI 
Uganda Research Unit on AIDS. Data access inquir-
ies can be made to the Director, MRC/UVRI, Uganda 
Research Unit on AIDS by email to: mrc@mrcuganda.org 
or the corresponding author.
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